<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911016-0131</DOCNO><DOCID>911016-0131.</DOCID><HL>   Technology:   Warner-Lambert Wins Approval</HL><DATE>10/16/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B9</SO><CO>   WLA</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>NEW JERSEY (NJ)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   MORRIS PLAINS, N.J. -- Warner-Lambert Co. said it receivedapproval from the Food and Drug Administration to market itsNipent leukemia treatment.   Nipent is a treatment for hairy-cell leukemia patients whodo not respond to standard therapy. Hairy-cell leukemiaaffects about 2,500 patients in the U.S., with up to 600 newpatients diagnosed each year.</LP><TEXT/></DOC>